哈药股份 (600664.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

22.3x

Market Cap

CNY 20.70B

MomentumView details →

1D Return

+0.61%

YTD Return

+125.51%

RSI (14)

48.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

22.3x

Market Cap

CNY 20.70B

RSI (14)

48.6

MomentumView details →

1D Return

+0.61%

YTD Return

+125.51%

ProfitabilityView details →

Gross Margin

25.32%

Net Margin

1.94%

EBITDA Margin

5.14%

ROE (TTM)

5.29%

ROA (TTM)

2.11%

Asset Turnover

1.10x

GrowthView details →

Revenue YoY

−1.50%

EPS YoY

−54.73%

FCF YoY

+14.85%

Revenue CAGR 3Y

+4.95%

EPS CAGR 3Y

−9.68%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.10

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

1.45x

Quick Ratio

1.17x

Div Yield

—

Div Rate

—

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

15.96B

Net Income (TTM)

309.80M

Op. CF (TTM)

718.17M

Latest newsMore news →

Harbin Pharmaceutical Group announced its first-half 2026 results: net profit attributable to shareholders of 410 million yuan, up 57.99% year-on-year.11d ago

Harbin Pharmaceutical announced that its subsidiaries Harbin General Factory and Harbin No.6 Factory have two products provisionally selected in the 12th national centralized drug procurement, with the procurement period lasting until December 31, 2029.33d ago

Similar companies

皓元医药688131.SH Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited00874.HK Viatris Inc.VTRS 天士力600535.SH HUTCHMED (China) Limited00013.HK 济川药业600566.SH Find similar companies →

Latest newsMore news →

Harbin Pharmaceutical Group announced its first-half 2026 results: net profit attributable to shareholders of 410 million yuan, up 57.99% year-on-year.11d ago Harbin Pharmaceutical announced that its subsidiaries Harbin General Factory and Harbin No.6 Factory have two products provisionally selected in the 12th national centralized drug procurement, with the procurement period lasting until December 31, 2029.33d ago